# Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes

> **NCT05629806** · PHASE3 · UNKNOWN · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Type 2 Diabetes
- Blood Glucose Fluctuation

## Interventions

- **DRUG:** Metformin plus pioglitazone
- **DRUG:** Acarbose

## Key facts

- **NCT ID:** NCT05629806
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-10
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05629806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05629806, "Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05629806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*